Share this article on:

Early Murine Polymicrobial Sepsis Predominantly Causes Renal Injury

Craciun, Florin L.*; Iskander, Kendra N.; Chiswick, Evan L.*; Stepien, David M.*; Henderson, Joel M.*; Remick, Daniel G.*

doi: 10.1097/SHK.0000000000000073
Basic Science Aspects
Editor's Choice

ABSTRACT: Multiple organ failure in sepsis substantially increases mortality. This study examined if there was greater hepatic, pancreatic, splenic, or renal injury in mice that would die during sepsis induced by cecal ligation and puncture (CLP) compared with that of those that would survive. Mice were stratified into groups predicted to die (Die-P) or predicted to live (Live-P) in the first 5 days after CLP based on plasma interleukin 6 levels. Groups were sacrificed to harvest organs for histology. Separate animals were followed for survival with daily blood sampling to examine renal function. No significant histological evidence of organ injury was observed in either the Live-P or Die-P mice. Minimal hepatic injury occurred as plasma aspartate transaminase demonstrated less than a 2-fold increase over normal in both groups. In addition, pancreatic injury was minimal as there was also less than a 2-fold increase in plasma amylase levels. In contrast, blood urea nitrogen levels were nearly five times higher within 24 h in Die-P mice compared with those of mice predicted to live. Mice with blood urea nitrogen levels higher than 44 mg/dL had a 17.6 higher relative risk of dying (95% confidence interval, 4.5–69.4). Cystatin C, a more specific kidney function biomarker, was also elevated at 24 h after CLP. When the cystatin C levels were analyzed relative to the hours before death, rather than hours after CLP, they were also significantly increased in mice Dead by day 5 compared with those Alive after day 5. We conclude that limited liver, pancreas, and spleen injury develops during murine CLP-induced sepsis while significant kidney injury is present. The renal injury becomes worse closer to death.

*Department of Pathology and Laboratory Medicine, Boston University School of Medicine, Boston, Massachusetts; and Department of Surgery, Boston University Medical Center, Boston, Massachusetts

Received 26 Aug 2013; first review completed 10 Sep 2013; accepted in final form 8 Oct 2013

Address reprint requests to Daniel Remick, MD, Department of Pathology and Laboratory Medicine, Boston University School of Medicine, 670 Albany St, Room 407, Boston, MA 02118. E-mail:

This work was supported by the National Institutes of Health (grant no. GM 82962 and grant no. T32 GM 86308 to D.G.R.).

Supplemental digital content is available for this article. Direct URL citation appears in the printed text and is provided in the HTML and PDF versions of this article on the journal’s Web site (

Back to Top | Article Outline


Mortality in sepsis remains intolerably high, with more than 200,000 patients dying each year in the United States alone (1). Severe sepsis has associated organ dysfunction (2). It is not completely understood how organ dysfunction and subsequent failure develop, and some hypothesize that they represent a protective mechanism because a decrease in function helps ensure the survival of organs faced with severe illness (3). However, the development of organ dysfunction is strongly correlated with increased mortality, and the more organs that fail, the higher the mortality, exceeding 80% for five failed organs (4).

The lungs are the organs that fail most frequently in septic patients (5), although a recent study published by our group has shown that mice die in the acute phase of cecal ligation and puncture (CLP)–induced sepsis without significant lung injury (6). After the lungs, the organ that fails most frequently in septic patients is the kidney (5), with as many as a third of the patients hospitalized with community-acquired pneumonia developing acute kidney injury (AKI) (7). In addition, approximately 50% of the patients who develop AKI have sepsis, making sepsis the leading cause of AKI in critical illness (8). The presence of both AKI and sepsis has an additive negative effect, with mortality rates about 70% (9), dramatically higher than those for patients who are only septic alone (1) or patients with AKI because of a different etiology (8). Acute kidney injury is not a uniform feature of the CLP model of sepsis as some investigators detect it with changes in serum blood urea nitrogen (BUN) and creatinine (10), whereas others do not (11). Acute kidney injury has also been reported to only be present in CLP sepsis in older animals (12). Recent publications elegantly described the dysfunction present in the renal tubules after CLP-induced sepsis (13) and the role of neutrophils in the development of AKI (14). More investigators document the development of AKI after CLP.

The hepatic system is not as frequently affected as the kidneys, but septic patients who have liver involvement have a very high mortality (1). Liver injury has been reported in the CLP model of sepsis (15). The pancreas has also been shown to be vulnerable during sepsis both in humans (16) and in animal models of the disease (17).

Given the controversy concerning the role of organ injury in sepsis mortality, as well as the issues concerning the utility of animal models (18), this study examined the association between sepsis mortality in the murine CLP model and injury of liver, pancreas, spleen, and kidney. The capacity to predict survival outcome in the first 5 days of murine intra-abdominal sepsis based on plasma interleukin 6 (IL-6) levels was used (19). Histology and markers of organ injury and function in mice predicted to die (Die-P) were compared with those of mice predicted to live (Live-P), with values from naive mice used as controls to determine normal ranges. Kidney function was also measured in a separate group of mice followed for survival until day 5 after CLP to allow comparison of results from mice within 24 h of their death with those from survivors. Overall, the intent of the study was not to demonstrate that CLP-induced sepsis causes organ injury but rather to determine what organs in mice predicted to die will have worse injury and could explain their survival outcome.

Back to Top | Article Outline



Female adult ICR (Institute of Cancer Research) outbred mice (8 weeks old, 20–25 g body weight) were used in this study (Harlan–Sprague Dawley, Inc., Indianapolis, Ind). Females were chosen because they will not fight when housed together. Mice were housed in transparent plastic cages containing wood chip bedding (five animals in each cage). Each mouse was considered separately for data analysis. Mice were acclimated to the temperature (21°C–23°C)- and humidity (30%–70%)-controlled housing room programmed for a 12-h light-dark cycle for at least 72 h before the start of the experiment. These housing conditions where maintained throughout the experiment. The animals were provided standard rodent chow and water ad libitum for the duration of the study. The animals included in the study were cared for and used according to the provisions of the PHS Policy on Humane Care and Use of Laboratory Animals and the Guide for the Care and Use of Laboratory Animals. The experiments were approved by Boston University Animal Care and Use Committee.

Back to Top | Article Outline

Sepsis model and sampling

Cecal ligation and puncture was performed according to our protocol (19), an adaptation of the original description (20). This model is based on the original description of the CLP model of sepsis (21, 22). Mice were initially anesthetized in an induction chamber by inhaling 5% isoflurane in 100% oxygen. After loss of consciousness, they were connected to a mask delivering 3% isoflurane in 100% oxygen for the duration of the surgical procedure. The cecum was ligated just below the ileocecal valve with 4-0 silk suture thread and double punctured with a 16-gauge needle to produce a mortality rate of approximately 50%. Immediately after surgery, mice were injected with 1 mL of normal saline subcutaneously (37°C) to replace fluid lost and help the recovery of body temperature. Pain medication was provided for the first 2 days after CLP (buprenorphine 0.05 mg/kg subcutaneously every 12 h; the first dose was given with the saline injection immediately after surgery and the other three doses were given with the antibiotic injections) and antibiotic treatment for the first 5 days after CLP (imipenem 25 mg/kg in 1 mL of D5W with Ringer’s lactate solution, subcutaneously, every 12 h, starting at 2 h after surgery). The medication regimen was followed until the moment of scheduled sacrifice, death, or study completion in the surviving mice. Before the start of the experiments, animals were assigned to be sacrificed at 6 h (n = 20) or 24 h after CLP (n = 53) or followed for survival until day 5 after CLP (n = 99). A group of naive mice (no intervention) was also sacrificed and sampled in the same manner (n = 24). For histology, additional mice were sacrificed at 24 h (n = 13) and 48 h (n = 15). The final separation of these animals in analysis groups was performed as detailed in the following section of the Materials and Methods.

A 20-μL sample of blood was collected before administration of anesthesia in the mice sacrificed at 6 and 24 h after CLP, as well as the sacrificed control mice. The facial vein puncture technique was used, and blood was retrieved with an EDTA (ethylenediaminetetraacetic acid, 169 mM tripotassium salt)–rinsed pipette tip. The blood was immediately diluted 1:10 in phosphate buffer saline (PBS) with 1:50 EDTA, and plasma was collected after centrifugation (1,000g) at 4°C for 5 min. In 20 mice followed for survival, blood was collected in a similar manner daily for the first 5 days after CLP (or until death), with the sample on day 1 collected at 6 h after the surgery. The plasma from these mice was used for measurements of BUN and cystatin C within 24 h of death. The other 79 mice followed for survival also had a 20-μL blood sample collected at 24 h after CLP. These samples were used to measure BUN and perform receiver-operator characteristic analysis to predict survival to day 5 after CLP. This higher number of mice is usually used in this type of analysis. After anesthesia (87 μg/g ketamine and 13 μg/g xylazine in 250 μL normal saline administered subcutaneously), blood was also collected from the retro-orbital venous plexus in mice that were sacrificed and was used to obtain undiluted plasma. This was used for the biochemical assays measuring aspartate transaminase (AST) and amylase that required a larger quantity of plasma. While still under anesthesia, euthanasia was performed by cervical dislocation, and death was confirmed by opening of the thoracic cavity. Liver, pancreas, spleen, and kidney tissue were collected from the sacrificed septic mice at 24 and 48 h after CLP, as well as from normal mice and fixed in 10% formalin.

Back to Top | Article Outline

Group stratification

To perform histological and some biochemical analyses, mice needed to be sacrificed, precluding determination of the actual survival outcome for these septic mice. Fortunately, information about their death or survival until after day 5 after CLP can be obtained by measuring plasma IL-6, a biomarker shown to be highly predictive of mortality in the CLP model of sepsis (19, 23). The septic mice sacrificed at 6 and 24 h were the same animals used for a recent publication that specifically addressed the issue of whether lung injury developed after CLP (6). Their survival outcome was predicted using a dual cutoff system for plasma IL-6 levels. At 6 h after CLP, plasma IL-6 levels higher than 14.8 ng/mL were used to predict death within the first 5 days (90% specificity), and levels less than 12.1 ng/mL predicted survival until after day 5 (95% sensitivity), with intermediate levels eliminated because of a higher chance of false-positive or false-negative results. Using this cutoff system, the 20 mice sacrificed at 6 h were separated into 11 predicted to die in the first 5 days after CLP (Die-P) and nine predicted to live until after day 5 after CLP (Live-P). A similar cutoff system was developed for plasma IL-6 values measured at 24 h after CLP, and the 53 mice sacrificed at that time point were separated in 14 Die-P (IL-6 higher than 12 ng/mL, 100% specificity) and 29 Live-P (IL-6 less than 1.5 ng/mL, 100% sensitivity) for biochemical analysis. The experiments where performed until up to 10 animals in each group were studied. Based on the IL-6 level at 24 h, mice included for histology were 8 Die-P and 5 Live-P at 24 h, as well as 7 Die-P and 8 Live-P at 48 h (for these experiments, five animals in each group were sought).

The animals in the survival experiments were separated into two groups: those that survived until after day 5 (Alive after day 5) and those that died within the first 5 days after CLP (Dead by day 5). This separation was based on the observed outcome and not on the plasma IL-6 prediction. To correlate BUN and IL-6 measurements, the values from individual mice were first log transformed and linear regression was performed.

Back to Top | Article Outline


Formalin-fixed kidney, pancreas, spleen, and liver tissues were embedded in paraffin and sectioned at 5 μm for routine histology. Slides were stained with hematoxylin and eosin (H&E) as well as periodic acid-Schiff reagent for kidney histology. The renal histology was evaluated by Joel Henderson, MD, a board-certified pathologist with fellowship training in renal pathology. The remaining slides were scored by Daniel Remick, MD, a board-certified pathologist. Both pathologists were blinded for group affiliation when they performed their assessment of the slides.

Back to Top | Article Outline

Biochemical measurements

The concentrations of BUN, AST, and amylase were measured by standard clinical chemistry techniques using kits from Pointe Scientific, Inc. (Canton, Mich).

Back to Top | Article Outline

Cystatin C measurement

The concentration of plasma cystatin C was measured by enzyme-linked immunosorbent assay using commercially available matched antibodies and recombinant protein standards (R&D Systems, Minneapolis, Minn). The enzyme-linked immunosorbent assay was performed similarly to our previously described protocol (24), but blocking was performed with 150 µL of Superblock Blocking Buffer in PBS (Pierce, Rockford, Ill), and the dilution buffer was PBS with 0.1% bovine serum albumin (Sigma Chemicals, St. Louis, Mo) and 0.005% Tween 20 (Surfact Amps, 10% Tween 20; Pierce, Rockford, Ill). The highest standard was 500 ng/mL, and six subsequent 1:3 dilutions were used to generate the standard curve.

Back to Top | Article Outline

Statistical analysis

Statistics were performed using Prism 5 (GraphPad Software). If more than two groups were compared, one-way analysis of variance followed by the Newman-Keuls posttest was used if the groups had normal distribution, whereas the Kruskal-Wallis test followed by Dunn posttest was used when the distribution was not normal. If two groups were compared, t tests were performed for normally distributed data and Mann-Whitney U tests were performed when data did not show normal distribution. A value of P < 0.05 was considered statistically significant. The receiver-operator characteristic curve analysis was performed to determine the capacity of BUN levels to predict the 5-day post-CLP survival outcome. The relative risk of death for the groups defined by the chosen cutoff (more than and less than 44 mg/dL) was also calculated using a contingency table analysis. To correlate BUN and IL-6 measurements, the values from individual mice were first log transformed and linear regression was performed.

Back to Top | Article Outline


Our model of CLP has an overall 28-day mortality rate of 50% (19, 25), and most of the deaths in the early phase (days 1–5) occur within the first 3 days. Therefore, samples collected at the 24-h time point from an animal predicted to die will likely be within 2 days of that outcome. There were no significant morphological changes observed in the liver, pancreas, or kidney in Live-P or Die-P mice compared with normal histology at 24 h (Fig. 1) or 48 h (see Figure, Supplemental Digital Content 1, at after CLP. No significant histological differences were seen in liver, pancreas, or kidney specimens from Live-P or Die-P mice at 48 h after CLP compared with those of normal animals. Both Live-P and Die-P spleens demonstrated characteristic postsepsis changes, as detailed in Figure 1. Hematoxylin and eosin slides were evaluated by light microscopy and photographed at 200× magnification. At 48 h, n = 8 for Live-P and n = 7 for Die-P. For control mice, n = 8. The spleens from the same CLP mice demonstrated extensive lymphocyte apoptosis, starry sky appearance, and congestion compared with those of naive mice. Hotchkiss et al. (26) have previously described significant splenic changes after CLP sepsis.

Histology is a relatively crude method to evaluate organ or cell injury. Therefore, biochemical tests were performed to evaluate liver, pancreas, and kidney damage. Normal values were established using plasma samples from naive mice, the same animals used for histology. Liver injury was assessed by measuring AST levels. At 6 h after CLP, the levels of AST were at the higher end of the normal range (as defined in Table 1) in both Live-P and Die-P (Fig. 2). There was a statistically significant increase in plasma AST by 24 h in both groups, with slightly higher levels in Die-P mice. However, the levels were less than 2-fold higher than normal for both groups, indicating only mild liver injury.

Serum amylase levels are commonly used to detect pancreatic injury. Amylase levels were slightly above normal 6 h after CLP in both Live-P and Die-P mice (Fig. 3). However, at 24 h, there was a significant increase in amylase levels for the Die-P mice. Because the levels were only 60% higher than normal, this probably indicates a statistically significant but biologically irrelevant pancreatic injury, with much higher levels being typically detected in the presence of severe pancreatitis.

Kidney injury has been traditionally detected by measurements of BUN and creatinine (27). At 6 h after CLP, the average levels of BUN for Live-P mice were slightly above the upper limit of normal (Fig. 4A). In Die-P at the same time point, they were significantly higher than the Live-P values and were almost 2-fold above normal. By 24 h, the BUN levels returned to normal in Live-P mice, but they continued to rise in Die-P mice to a level almost five times higher than Live-P at the same time point. These changes in BUN are similar to the alterations observed in plasma levels of IL-6 (25, 28). We compared BUN and IL-6 and demonstrated a close correlation between the two measurements (Fig. 4B).

Interleukin 6 levels predict whether mice will die before the end of day 5 after CLP (23), but the exact day of death is still uncertain. To measure the BUN levels closer to the time of death, mice underwent CLP and then had blood samples collected daily until death or the end of the experiment on day 5 after CLP. The BUN levels recorded within the last 24 h of life (last sample collected before death) for the animals that succumbed to sepsis (Dead by day 5) were above normal and significantly higher than the levels recorded at corresponding time points in mice that survived past day 5 (Fig. 5A).

The considerable difference between Live-P and Die-P murine BUN levels at 24 h after CLP observed in Figure 4 suggests that BUN may be able to predict sepsis survival. To test this idea, CLP was performed and animals were followed for survival until after day 5 and retrospectively separated into two groups: Dead by day 5 and Alive after day 5. Note that these groups were not the same as those predicted to live or die based on plasma IL-6. The BUN levels were measured in samples collected at 24 h after CLP from these mice (Fig. 5B). The mean BUN levels recorded were virtually identical to the BUN levels in mice separated based on IL-6 survival prediction in Figure 4 (Alive after day 5 versus Live-P and Dead by day 5 versus Die-P). A receiver-operator characteristic curve analysis was performed based on the data in Figure 5, and the area under the curve was 0.96, indicating excellent prediction capability (Fig. 5C). A cutoff level of 44 mg/dL predicted the outcome, with 92% sensitivity and 85% specificity. Mice with BUN levels higher than 44 mg/dL had a relative risk for mortality of 17.6 (95% confidence interval, 4.5–69.4) compared with the mice with lower levels. The data in Figures 4 and 5 indicate that kidney injury develops in the first 24 h of the evolution of sepsis in mice that will succumb to the disease.

A more specific marker of kidney function, cystatin C, was also measured at 24 h after CLP. Within 24 h, the cystatin C levels of both Live-P and Die-P mice were higher than those in normal mice (Fig. 6A). The difference between the Live-P and Die-P was small but statistically significant. Levels of this biomarker are considered to increase early in the development of kidney injury (27), and this small increase at 24 h could be exacerbated closer to death in Die-P mice if development of injury is a fast preterminal event.

To test if increased kidney injury develops closer to death in septic animals, mice were followed for survival until after day 5 after CLP and had their daily blood samples used to measure cystatin C (same mice as in Fig. 5A). The cystatin C levels were measured in samples collected within 24 h of death from mice that succumbed during the first 5 days after CLP and compared with levels measured at matched time points in mice that survived until after day 5. As seen in Figure 6B, the mean of the cystatin C levels of the survivors was similar to normal value. The nonsurvivors, however, had significantly higher levels than the survivors and normal mice. The mean for the levels in Dead by day 5 was 2.4 times higher than the mean of the normal mice. Taken together, the data presented in Figure 6 indicate that more significant kidney injury develops closer to death in septic mice, particularly in the last 24 h.

Back to Top | Article Outline


Liver, pancreas, spleen, and kidney injuries were evaluated in the murine CLP model of sepsis to determine if their presence could explain the pathophysiology of why some animals die while others survive. The histology of liver, pancreas, and kidney tissues was unremarkable 24 or 48 h into the evolution of sepsis for both mice predicted to die and survive. Other than changes such as lymphocyte apoptosis in the spleens of both groups, the lack of histological findings is consistent with the situation in human sepsis (26) and confirms CLP as a model for sepsis research that more closely reflects the human pathology. It should be noted that the current study compared the histology of septic mice predicted to die with that of septic mice predicted to live, whereas most previous studies compare septic mice with normal mice. The similarities between the CLP model of sepsis and human sepsis are shown in the Table, Supplemental Digital Content 2, at Our group has also recently published that there is no significant lung injury or dysfunction in the murine CLP model of sepsis (6). In the current study, some biomarker measurements of organ injury were elevated, particularly at 24 h after CLP in the mice predicted to die. Biologically significant injury, however, was only found for the kidneys, especially within the last 24 h of life for the animals that died after CLP. Although the association of sepsis and AKI is clearly established (8), our findings highlight the importance and timing of kidney injury in the murine CLP sepsis model.

Increased levels of AST, amylase, BUN, and cystatin C indicate a level of multiple organ injury. Two alternate hypotheses exist to explain the findings. Multiple small insults to different organ systems could act in combination/synergy to produce lethality in murine sepsis. However, the levels measured would not be expected to indicate substantial alterations in organ function. More likely, intra-abdominal sepsis causes a mild degree of multiple organ damage but not overt failure of the liver, pancreas, or kidney at this time point. In models of acetaminophen-induced acute liver injury, AST levels of 15,000 U/L were reported at 24 h, representing more than a 50-fold increase over those seen in our septic mice (29). Amylase in lethal acute pancreatitis measured more than 12,000 U/L, higher than an 8-fold elevation compared with our CLP mice (30). In our current study, BUN levels of 90 mg/dL approached those seen in a lethal model of renal ischemia-reperfusion injury of about 98 mg/dL at 24 h (31). There may be progressive organ injury closer to death, and the measurements for cystatin C indicated that more significant kidney injury did develop in 24 h before death in nonsurviving mice. Obtaining histological evidence for this increased kidney injury is not feasible with current methods. The prediction based on plasma IL-6 levels indicates whether the animal will die in the first 5 days after CLP but not the exact moment.

The pancreatic blood supply seems to be affected earlier than that of other organs in sepsis (32), raising the possibility of increased injury. A small elevation in amylase levels was detected for Die-P mice at 24 h, indicative of only limited injury at this time point in the evolution of sepsis (33). The levels reached are consistent with previously described findings in sepsis studies using the murine CLP model (34). Similarly, the AST levels suggest only mild liver injury at 24 h and only slightly worse in mice predicted to die. A recent study does show an increasing trend in AST levels until 48 h after CLP in nonsurvivors, but this was in the setting of a double-hit model (sepsis after trauma/hemorrhage) (35). Even though closer to death, the level of kidney injury seems significant, because 24 h before death, there was a substantial increase compared with those of mice that survived, as indicated by cystatin C levels in this study. Examining these organs together, it is apparent that a small degree of multiple organ injury manifests at 24 h into the progression of CLP sepsis, particularly in the animals that were going to die. Because limited blood volume can be collected in our nonlethal serial sampling technique, daily monitoring of AST and amylase levels was not possible with our techniques. Consequently, we could not test if the progression to overt kidney injury in dying mice is also associated with severe liver and pancreas injury throughout the acute phase.

Historically, serum creatinine has been the most frequently used endogenous marker for estimating the glomerular filtration rate (GFR). However, it is not considered ideal because the levels are influenced by factors, such as diet, muscle mass, sex, race, and age; it is actively secreted by the proximal tubules that can lead to a 10% to 40% overestimation of the GFR; and it does not work well for detecting smaller decreases, that is, less than 40% of GFR (36). Cystatin C, a 13-kd endogenous cystein proteinase inhibitor, has recently been proposed to be a better marker for GFR, and two meta-analyses that looked at more than 100 studies comparing it with serum creatinine have confirmed this (37, 38). Cystatin C has previously been used to diagnose AKI in the CLP model (39). It is constantly produced by a housekeeping-type gene in all nucleated cells, without being affected by muscle mass, sex, or age. It is freely filtered by the glomeruli and not secreted by tubular cells, but it is reabsorbed and fully catabolized by proximal renal tubular cells. Serum cystatin C has been shown to be the best for early detection of AKI or for diagnosis of already established AKI (27). Cystatin C has also been shown to be a more sensitive and earlier marker for renal dysfunction than BUN and creatinine in mouse models of AKI (40).

Some of the formulas based on cystatin C indicate a linear relation between GFR and the reciprocal of serum cystatin C (41). This indicates that the increase in cystatin C levels seen in this study for septic mice within 24 h of death would correspond to a decrease of more than 50% in GFR, indicative of injury by the RIFLE classification criteria (42). Although this study did not attempt to uncover mechanisms of kidney injury in sepsis, a better understanding of the moment when it happens after CLP should help future mechanistic studies. A 2010 report of cystatin C levels in CLP sepsis found no difference between sham- and CLP-operated rats, but the values obtained were about 10 times lower than in our study (43). This could be an interspecies difference because our levels are more in line with previous reports of kidney injury in mice (39, 40) or caused by a difference in illness severity modulated by the lethality of the septic insult.

As a marker of kidney function, BUN has been considered to be even less specific than creatinine because its levels are affected, apart from glomerular filtration, by tubular reabsorption and also by the rate of its production, which in turn is influenced by protein intake, tissue protein catabolism, gastrointestinal bleeding, and corticosteroid therapy. As such, urea nitrogen is a reflection of many simultaneous pathological processes. The timing of some of these processes in CLP sepsis could explain why the BUN values measured in the last 24 h of life decrease when compared with those measured at 24 h after CLP, while the more specific marker of kidney function, cystatin C, increased in the same time span. Blood urea nitrogen levels higher than 40 mg/dL on admission to the intensive care unit were associated with increased mortality in critically ill patients, particularly at 30 days but even up to a year (44). The same BUN levels were also associated with a higher risk of positive blood cultures. From the data obtained in our study, a level of 44 mg/dL at 24 h after CLP was highly predictive of 5-day mortality, indicating that BUN could be useful as a biomarker for sepsis mortality. In addition, there was a close correlation of BUN and IL-6 (a well-established biomarker for sepsis mortality).

Back to Top | Article Outline


1. Angus DC, Linde-Zwirble WT, Lidicker J, Clermont G, Carcillo J, Pinsky MR: Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care. Crit Care Med 29 (7): 1303–1310, 2001.
2. Levy MM, Fink MP, Marshall JC, Abraham E, Angus D, Cook D, Cohen J, Opal SM, Vincent JL, Ramsay G: 2001 SCCM/ESICM/ACCP/ATS/SIS International Sepsis Definitions Conference. Crit Care Med 31 (4): 1250–1256, 2003.
3. Singer M, De Santis V, Vitale D, Jeffcoate W: Multiorgan failure is an adaptive, endocrine-mediated, metabolic response to overwhelming systemic inflammation. Lancet 364 (9433): 545–548, 2004.
4. Marshall JC, Cook DJ, Christou NV, Bernard GR, Sprung CL, Sibbald WJ: Multiple organ dysfunction score: a reliable descriptor of a complex clinical outcome. Crit Care Med 23 (10): 1638–1652, 1995.
5. Martin GS, Mannino DM, Eaton S, Moss M: The epidemiology of sepsis in the United States from 1979 through 2000. N Engl J Med 348 (16): 1546–1554, 2003.
6. Iskander KN, Craciun FL, Stepien DM, Duffy ER, Kim J, Moitra R, Vaickus LJ, Osuchowski MF, Remick DG: Cecal ligation and puncture–induced murine sepsis does not cause lung injury. Crit Care Med 41 (1): 159–170, 2013.
7. Murugan R, Karajala-Subramanyam V, Lee M, Yende S, Kong L, Carter M, Angus DC, Kellum JA: Acute kidney injury in non-severe pneumonia is associated with an increased immune response and lower survival. Kidney Int 77 (6): 527–535, 2010.
8. Bagshaw SM, Uchino S, Bellomo R, Morimatsu H, Morgera S, Schetz M, Tan I, Bouman C, Macedo E, Gibney N, et al.: Septic acute kidney injury in critically ill patients: clinical characteristics and outcomes. Clin J Am Soc Nephrol 2 (3): 431–439, 2007.
9. Yegenaga I, Hoste E, Van Biesen W, Vanholder R, Benoit D, Kantarci G, Dhondt A, Colardyn F, Lameire N: Clinical characteristics of patients developing ARF due to sepsis/systemic inflammatory response syndrome: results of a prospective study. Am J Kidney Dis 43 (5): 817–824, 2004.
10. Matsukawa A, Kaplan MH, Hogaboam CM, Lukacs NW, Kunkel SL: Pivotal role of signal transducer and activator of transcription (Stat)4 and Stat6 in the innate immune response during sepsis. J Exp Med 193 (6): 679–688, 2001.
11. Pedersen PV, Warner BW, Bjornson HS, Hiyama DT, Li S, Rigel DF, Hasselgren PO, Fischer JE: Hemodynamic and metabolic alterations during experimental sepsis in young and adult rats. Surg Gynecol Obstet 168 (2): 148–156, 1989.
12. Miyaji T, Hu X, Yuen PS, Muramatsu Y, Iyer S, Hewitt SM, Star RA: Ethyl pyruvate decreases sepsis-induced acute renal failure and multiple organ damage in aged mice. Kidney Int 64 (5): 1620–1631, 2003.
13. Watts BA 3rd, George T, Sherwood ER, Good DW: A two-hit mechanism for sepsis-induced impairment of renal tubule function. Am J Physiol Renal Physiol 304 (7): F863–F874, 2013.
14. Castoldi A, Braga TT, Correa-Costa M, Aguiar CF, Bassi EJ, Correa-Silva R, Elias RM, Salvador F, Moraes-Vieira PM, Cenedeze MA, et al.: TLR2, TLR4 and the MYD88 signaling pathway are crucial for neutrophil migration in acute kidney injury induced by sepsis. PLoS One 7 (5): e37584, 2012.
15. Deutschman CS, Cereda M, Ochroch EA, Raj NR: Sepsis-induced cholestasis, steatosis, hepatocellular injury, and impaired hepatocellular regeneration are enhanced in interleukin-6-/- mice. Crit Care Med 34 (10): 2613–2620, 2006.
16. Tribl B, Madl C, Mazal PR, Schneider B, Spitzauer S, Vogelsang H, Gangl A: Exocrine pancreatic function in critically ill patients: septic shock versus non-septic patients. Crit Care Med 28 (5): 1393–1398, 2000.
17. Florholmen J, Revhaug A, Burhol PG, Giercksky KE, Olsen RL: Effect of intravenous and intraduodenal administration of Escherichia coli endotoxin on the porcine pancreas as evaluated by changes in the serum cationic trypsin-like immunoreactivity. Scand J Gastroenterol 20 (3): 279–284, 1985.
18. Seok J, Warren HS, Cuenca AG, Mindrinos MN, Baker HV, Xu W, Richards DR, McDonald-Smith GP, Gao H, Hennessy L, et al.: Genomic responses in mouse models poorly mimic human inflammatory diseases. Proc Natl Acad Sci U S A 110 (9): 3507–3512, 2013.
19. Craciun FL, Schuller ER, Remick DG: Early enhanced local neutrophil recruitment in peritonitis-induced sepsis improves bacterial clearance and survival. J Immunol 185 (11): 6930–6938, 2010.
20. Wichterman KA, Baue AE, Chaudry IH: Sepsis and septic shock—a review of laboratory models and a proposal. J Surg Res 29 (2): 189–201, 1980.
21. Baker CC, Chaudry IH, Gaines HO, Baue AE: Evaluation of factors affecting mortality rate after sepsis in a murine cecal ligation and puncture model. Surgery 94: 331–335, 1983.
22. Hubbard WJ, Choudhry M, Schwacha MG, Kerby JD, Rue LW 3rd, Bland KI, Chaudry IH: Cecal ligation and puncture. Shock 24 (Suppl 1): 52–57, 2005.
23. Remick DG, Bolgos GR, Siddiqui J, Shin J, Nemzek JA: Six at six: interleukin-6 measured 6 h after the initiation of sepsis predicts mortality over 3 days. Shock 17 (6): 463–467, 2002.
24. Nemzek JA, Siddiqui J, Remick DG: Development and optimization of cytokine ELISAs using commercial antibody pairs. J Immunol Methods 255 (1-2): 149–157, 2001.
25. Osuchowski MF, Craciun F, Weixelbaumer KM, Duffy ER, Remick DG: Sepsis chronically in MARS: systemic cytokine responses are always mixed regardless of the outcome, magnitude, or phase of sepsis. J Immunol 189 (9): 4648–4656, 2012.
26. Hotchkiss RS, Swanson PE, Freeman BD, Tinsley KW, Cobb JP, Matuschak GM, Buchman TG, Karl IE: Apoptotic cell death in patients with sepsis, shock, and multiple organ dysfunction. Crit Care Med 27 (7): 1230–1251, 1999.
27. Trof RJ, Di Maggio F, Leemreis J, Groeneveld AB: Biomarkers of acute renal injury and renal failure. Shock 26 (3): 245–253, 2006.
28. Osuchowski MF, Welch K, Siddiqui J, Remick DG: Circulating cytokine/inhibitor profiles reshape the understanding of the SIRS/CARS continuum in sepsis and predict mortality. J Immunol 177 (3): 1967–1974, 2006.
29. Yang R, Zhang S, Kajander H, Zhu S, Koskinen ML, Tenhunen J: Ringer’s lactate improves liver recovery in a murine model of acetaminophen toxicity. BMC Gastroenterol 11: 125, 2011.
30. Noji T, Nan-ya K, Mizutani M, Katagiri C, Sano J, Takada C, Nishikawa S, Karasawa A, Kusaka H: KF24345, an adenosine uptake inhibitor, ameliorates the severity and mortality of lethal acute pancreatitis via endogenous adenosine in mice. Eur J Pharmacol 454 (1): 85–93, 2002.
31. Hu H, Zou C, Xi X, Shi Z, Wang G, Huang X: Protective effects of pioglitazone on renal ischemia-reperfusion injury in mice. J Surg Res 178 (1): 460–465, 2012.
32. Hiltebrand LB, Krejci V, Banic A, Erni D, Wheatley AM, Sigurdsson GH: Dynamic study of the distribution of microcirculatory blood flow in multiple splanchnic organs in septic shock. Crit Care Med 28 (9): 3233–3241, 2000.
33. Banks PA, Freeman ML: Practice guidelines in acute pancreatitis. Am J Gastroenterol 101 (10): 2379–2400, 2006.
34. Liaudet L, Mabley JG, Soriano FG, Pacher P, Marton A, Hasko G, Szabo C: Inosine reduces systemic inflammation and improves survival in septic shock induced by cecal ligation and puncture. Am J Respir Crit Care Med 164 (7): 1213–1220, 2001.
35. Drechsler S, Weixelbaumer KM, Redl H, van Griensven M, Bahrami S, Osuchowski MF: Experimentally approaching the ICU: monitoring outcome-based responses in the two-hit mouse model of posttraumatic sepsis. J Biomed Biotechnol 2011: 357926, 2011.
36. Perrone RD, Madias NE, Levey AS: Serum creatinine as an index of renal function: new insights into old concepts. Clin Chem 38 (10): 1933–1953, 1992.
37. Dharnidharka VR, Kwon C, Stevens G: Serum cystatin C is superior to serum creatinine as a marker of kidney function: a meta-analysis. Am J Kidney Dis 40 (2): 221–226, 2002.
38. Laterza OF, Price CP, Scott MG: Cystatin C: an improved estimator of glomerular filtration rate? Clin Chem 48 (5): 699–707, 2002.
39. Kang K, Nan C, Fei D, Meng X, Liu W, Zhang W, Jiang L, Zhao M, Pan S: Heme oxygenase 1 modulates thrombomodulin and endothelial protein C receptor levels to attenuate septic kidney injury. Shock 40 (2): 136–143, 2013.
40. Song S, Meyer M, Turk TR, Wilde B, Feldkamp T, Assert R, Wu K, Kribben A, Witzke O: Serum cystatin C in mouse models: a reliable and precise marker for renal function and superior to serum creatinine. Nephrol Dialysis Transplant 24 (4): 1157–1161, 2009.
41. Tidman M, Sjostrom P, Jones I: A comparison of GFR estimating formulae based upon s-cystatin C and s-creatinine and a combination of the two. Nephrol Dialysis Transplant 23 (1): 154–160, 2008.
42. Bellomo R, Ronco C, Kellum JA, Mehta RL, Palevsky P: Acute renal failure—definition, outcome measures, animal models, fluid therapy and information technology needs: the Second International Consensus Conference of the Acute Dialysis Quality Initiative (ADQI) Group. Crit Care 8 (4): R204–R212, 2004.
43. Schick MA, Isbary TJ, Schlegel N, Brugger J, Waschke J, Muellenbach R, Roewer N, Wunder C: The impact of crystalloid and colloid infusion on the kidney in rodent sepsis. Intensive Care Med 36 (3): 541–548, 2010.
44. Beier K, Eppanapally S, Bazick HS, Chang D, Mahadevappa K, Gibbons FK, Christopher KB: Elevation of blood urea nitrogen is predictive of long-term mortality in critically ill patients independent of “normal” creatinine. Crit Care Med 39 (2): 305–313, 2011.

Renal injury; cystatin; BUN; AST; amylase; IL-6; biomarker

Supplemental Digital Content

Back to Top | Article Outline
© 2014 by the Shock Society